1Yanagisawa M, Kurihara H, Kimura S, et al. A novel polent vasoconstrictor peptide produced by vascular endothelial cells [ J ]. Nature, 1988,332 (6163) :411-415.
3Luscher TF, Barton M. Eodothelins and endothelin receptor antagnnists:therapeutic considerations for a novel class of cardiovascular drugs[ J ]. Circulation ,2000,102 ( 19 ) :2434-2440.
4Caligiuri G, Levy B, Pernow J, et al. Myocardial infarction mediated by endothelin receptor signaling in hypercholesterolemic mice[ J]. Proc Natl Acad Sci USA, 1999,96(12) :6920-6924.
5Zhang X,Zhao F, Xu C,et al. Circadian rhythm disorder of thrombosis and thrombolysis-related gene expression in apolipoprotein E knock-out mice[J]. Int J Mol Med,2008,22(2 ) : 149-153.
6Niccoli G,Lanza GA, Shaw S, et al. Endothelin-1 and acute myocardial infarction:a no-reflow mediator after successful percutaneous myocardial revascularization [ J ]. Eur Heart J, 2006,27 (15) : 1793-1798.
7Giaid A, Michel RP, Stewart D J, et al. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis [ J ]. Lancet, 1993,341 (8860) : 1550-1554.
8Kedzierski RM, Yanagisawa M. Endothelin system : the double-edged sword in health and disease[ J]. Annu Rev Pharmacol Toxicol, 2001,41 (6) :851-876.
9Kirchengast M, Luz M. Endothelin receptor antagonists: clinical realities and future directions [ J ]. J Cardiovasc, Pharmacol,2005, 45(2) :182-191.
10Sitbon O, Badesch DB, Channick RN,et al. Effects of the dualendothelin receptor antagonist bosentan in patients with pul-monary arterial hypertension : a 1-year follow-up study[J]. Chest, 2003, 124( 1 ) :247-254.
